Education

2004-2009   Ph.D. in Immunology, St Jude Children's Research Hospital, USA

1999-2003   B.S. in Biochemistry, Nanjing University 

 

Academic Experience

2025-present  Scientist, Changping Laboratory

2021-2025      ShanghaiTech University,Tenured Associate Professor

2015-2021      ShanghaiTech University, Assistant Professor (Tenure Track)

2009-2015      Postdoctoral Fellow in Immunology, University of California, San Francisco (UCSF)

Overview of Academic Research

Professor Haopeng Wang, who specializes cancer immunology, is a leading scientist in immune cell therapy in China. In recent years, he has published research in high-impact journals such as Cell (2025), Immunity (2024, 2020), Cell Research (2024, 2023), Nature Structural & Molecular Biology (2023), and Developmental Cell (2023). He has also been invited to write reviews and commentaries on immunotherapy for mainstream journals including Nature Metabolism (2024), Cell Stem Cell (2024), Cell Research (2024), Immunological Reviews (2023), and Trends in Cancer (2022).

 

His team recently developed the recyclable CAR-T technology, which has been licensed out to a leading CAR-T company and has entered multiple clinical trials (NCT05290155, NCT06307054). Recently, he developed an AI-driven CAR-T design platform - CAR-Toner, which has provided services to over 1,300 CAR-T research teams across 30 countries worldwide. In collaboration with BeiGene, a leading Chinese pharmaceutical company, he has developed a biomarker for predicting the efficacy of LAG3 immune checkpoint drugs, which has completed clinical validation.

Honors and Awards

1. 2024, Elected as SANS Explore Scholar

2.  2023, Shanghai Academic Research Leader

3.  2015, National High-Level Talent Program

Representative Research Achievements 

1.  Jiang Y, Dai A, Huang Y, Li H, Cui J, Yang H, Si L, Jiao T, Ren Z, Zhang Z, Mou S, Zhu H, Guo W, Huang Q, Li Y, Xue M, Jiang J, Wang F, Li L, Zhong Q, Wang K, Liu B, Wang J, Fan G, Guo J, Chen L, Workman CJ, Shen Z, Kong Y, Vignali DAA, Xu C, Wang H. Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of signaling motifs. Cell. 2025 May 1;188(9):2354-2371.e18. doi: 10.1016/j.cell.2025.02.014.（2025）

2.  Xu X, Chen H, Ren Z, Xu X, Wu W, Yang H, Wang J, Zhang Y, Zhou Q, Li H, Zhang S, Wang H, Xu C. Phase separation of chimeric antigen receptor promotes immunological synapse maturation and persistent cytotoxicity. Immunity. 2024 Dec 10;57(12):2755-2771.e8. doi: 10.1016/j.immuni.2024.11.005. （2024）

3.  Qiu S, Chen J, Wu T, Li L, Wang G, Wu H, Song X, Liu X, Wang H. CAR-Toner: an AI-driven approach for CAR tonic signaling prediction and optimization.   Cell Res. 2024 May;34(5):386-388. doi: 10.1038/s41422-024-00936-1. (2024)

4.  Chen J, Qiu S, Li W, Wang K, Zhang Y, Yang H, Liu B, Li G, Li L, Chen M, Lan J, Niu J, He P, Cheng L, Fan G, Liu X, Song X, Xu C, Wu H, Wang H. Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness. Cell Res. 2023 May;33(5):341-354. doi: 10.1038/s41422-023-00789-0. (2023)

5.  Niu J, Qiu H, Xiang F, Zhu L, Yang J, Huang C, Zhou K, Tong Y, Cai Y, Dong B, Lu Y, Sun X, Wan L, Ding X, Wang H, Song X. Correction: CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study. Blood Cancer J. 2023 Apr 13;13(1):52. doi: 10.1038/s41408-023-00825-7. Erratum for: Blood Cancer J. 2023 Mar 24;13(1):44. doi: 10.1038/s41408-023-00813-x.(2023)

6.  Mao Q, Ye Q, Xu Y, Jiang J, Fan Y, Zhuang L, Liu G, Wang T, Zhang Z, Feng T, Kong S, Lu J, Zhang H, Wang H, Lin CP. Murine trophoblast organoids as a model for trophoblast development and CRISPR-Cas9 screening. Dev Cell. 2023 Dec 18;58(24):2992-3008.e7. doi: 10.1016/j.devcel.2023.11.007. (2023)

7.  Wang H, Song X, Shen L, Wang X, Xu C. Exploiting T cell signaling to optimize engineered T cell therapies. Trends Cancer. 2022 Feb;8(2):123-134. doi: 10.1016/j.trecan.2021.10.007.(2022)

8.  Wang Y, Wang F, Wang L, Qiu S, Yao Y, Yan C, Xiong X, Chen X, Ji Q, Cao J, Gao G, Li D, Zhang L, Guo Z, Wang R, Wang H, Fan G. NAD+ supplement potentiates tumor-killing function by rescuing defective TUB-mediated NAMPT transcription in tumor-infiltrated T cells. Cell Rep. 2021 Aug 10;36(6):109516. doi: 10.1016/j.celrep.2021.109516. (2021)

9.  Li W, Qiu S, Chen J, Jiang S, Chen W, Jiang J, Wang F, Si W, Shu Y, Wei P, Fan G, Tian R, Wu H, Xu C, Wang H. Chimeric Antigen Receptor Designed to Prevent Ubiquitination and Downregulation Showed Durable Antitumor Efficacy. Immunity. Aug 18;53(2):456-470.e6. doi: 10.1016/j.immuni.2020.07.011. (2020)

10. Shang W, Jiang Y, Boettcher M, Ding K, Mollenauer M, Liu Z, Wen X, Liu C, Hao P, Zhao S, McManus MT, Wei L, Weiss A, Wang H. Genome-wide CRISPR screen identifies FAM49B as a key regulator of actin dynamics and T cell activation.  Proc Natl Acad Sci USA. 2018 Apr 24;115(17): E4051-E4060. doi: 10.1073/pnas.1801340115. (2018)